<DOC>
	<DOCNO>NCT00980200</DOCNO>
	<brief_summary>The study multi-center , double-blind , placebo-controlled , cross-over study evaluate efficacy safety select dos dose interval novel long act beta agonist ( LABA ) , GW642444 asthmatic subject ≥18 year age currently receive inhale corticosteroid treatment .</brief_summary>
	<brief_title>Efficacy Safety Study Subjects With Asthma</brief_title>
	<detailed_description>The study five-period cross-over study 7 day treatment period separate 7 day wash-out period . The study enroll asthmatic subject ≥18 year age currently receive inhale corticosteroid treatment FEV1 40-85 % predict normal airway reversibility demonstrate increase FEV1 ≥12 % ≥200ml . Efficacy assessment include 24-hour serial lung function test . Safety assessment include incidence adverse event measurement vital sign .</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<criteria>Outpatient ≥18 year age Visit 1 Male Eligible Female Diagnosis asthma least 12 week prior Visit 1 Disease reversibility Current antiasthma therapy Appropriately sign date informed consent obtain Able comply study requirement History LifeThreatening Asthma No use systemic corticosteroid indication within 8 week prior Visit No concurrent diseases/abnormalities would put safety subject risk study participation Drug Allergy β2 agonist sympathomimetic drug , know suspected sensitivity lactose magnesium stearate History severe milk protein allergy Noncompliance study medication studyrelated requirement No use inhale tobacco product within past three month historical use 10 pack year Administration prohibit medication nondrug therapy correspond timeframes outline protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>GW642444</keyword>
	<keyword>daily dose</keyword>
	<keyword>asthma</keyword>
	<keyword>efficacy</keyword>
	<keyword>safety</keyword>
	<keyword>FEV1</keyword>
</DOC>